HCT 116 cell invasiveness

HCT 116 cell invasiveness is a phenotypic measure of the metastatic potential of the HCT 116 human colorectal carcinoma cell line, rather than a specific molecular target like a protein or receptor. The HCT 116 line is a well-characterized, aggressive epithelial-like cell line derived from a male patient with colon cancer, frequently utilized in oncology research to study the mechanisms of tumor progression and metastasis (Source: ATCC CCL-247). The invasive phenotype involves a complex biological program where cells lose their polarities (epithelial-mesenchymal transition), gain migratory capacity, and secrete proteolytic enzymes such as matrix metalloproteinases to degrade the surrounding extracellular matrix (Source: PubMed, PMID: 29754167). While 'invasiveness' is a critical endpoint in drug discovery assays, it represents the collective outcome of multiple signaling cascades, including the Wnt/beta-catenin, TGF-beta, and MAPK pathways (Source: PubMed, PMID: 31050924). Therapeutic agents do not target 'invasiveness' directly; instead, they target the underlying molecular drivers that promote this behavior, such as specific kinases or transcription factors. Consequently, HCT 116 cell invasiveness is categorized as an experimental readout for evaluating the efficacy of anti-metastatic compounds in colorectal cancer models (Source: PubMed, PMID: 25682316).

Other names

HCT116 invasionHCT 116 metastatic potentialHCT 116 cell migrationColorectal cancer cell invasion

Not applicable as this is a phenotypic process; drugs affecting this process typically inhibit upstream signaling pathways such as Wnt/beta-catenin, TGF-beta, or PI3K/Akt, or inhibit downstream effectors like matrix metalloproteinases (MMPs).